20% of Recent Diabetes Diagnoses Found in 18-30 Age Group, Fitterfly Study Reveals

Written by Susi, Arushi Sharma

The Fitterfly Study has brought to light an alarming revelation – a significant 20% of recent diabetes diagnoses are occurring in the 18 to 30 age group.

20% of Recent Diabetes Diagnoses Found in 18-30 Age Group, Fitterfly Study Reveals
Discover the latest findings from the Fitterfly Study, which reveal that a surprising 20% of recent diabetes diagnoses have been detected among individuals aged 18 to 30. 

Fitterfly, a health-tech company, analyzed 16,000 digital interactions among pre-diabetes and diabetes individuals using the diabetes reversal calculator. This offers insights amidst rising diabetes cases – over 101 million current, plus 136 million pre-diabetic.

Among the key findings, it was revealed that 30% of the analyzed individuals had HbA1C levels above 9.5%. Such high HbA1C levels can cause several complications, making it necessary to take immediate action. Surprisingly, 22% of the 30% with these high levels took no medication and were looking for alternatives. The data also exposed a concerning trend—diabetes prevalence is on the rise among the younger generation.

20% of people with diabetes were between the ages of 18 and 30. 60% of those with diabetes were between the ages of 18 and 45. The company said in a statement that the onset of diabetes earlier in life "threatens the demographic dividend, public health, and economic growth of the nation."

The data reveals a worrying lack of commitment to diabetes care, regardless of diagnosis. Even with a family history in 70%, preventive efforts are scarce. 30% without family history emphasizes lifestyle’s role.

“On the back of latest studies showing increasing diabetes prevalence in the country, our study shows that a large number of people with diabetes are young, have poor glycemic control and are not taking diabetes medications. This is where a personalized approach driven by technology can contribute, including customized diet plans using the power of CGM devices, tailored exercise routines, stress management, and increasing compliance to appropriate medication."

In a statement, Dr. Arbinder Singal, Co-Founder and CEO of Fitterfly, said that data from our diabetes programs was presented at the American Diabetes Association annual conference in 2022. He added -

"We showed a reduction of HbA1c of 1.69% in 3 months, which is equivalent to the outcomes with a conventional diabetes drug therapy and has zero side effects."

Dr. Singal proposed programs to enhance outcomes and change India’s diabetes trend for uncontrolled cases. He further added -

“The study also shows that a lot of young adults with diabetes are looking for alternative approaches to diabetes management as the first line of therapy and our data shows that a diabetes remission approach may be more acceptable and effective in the first 5 years of diabetes.”

Fitterfly and ICMR-INDIAB-17, two studies that shed light on the topic of health, offer crucial insights. Cites and rural areas are alike in risk, needing effective diabetes care for all.

Share article